Evexomostat (SDX-7320) Reduces Obesity-Driven Tumor Growth
This publication from SynDevRx examines the dual anti-obesity and anti-tumor effects of Evexomostat (SDX-7320), a METAP2 inhibitor evaluated in diet-induced obese mouse and rat models. Using Next-Generation Metabolomics from Panome Bio, the study reveals distinct...
Untargeted Metabolomic & Lipidomic Profiles of Periodontitis Patients
Our partners at Indiana University leveraged Next-Generation Metabolomics to profile metabolic and lipidomic changes in gingival crevicular fluid from healthy individuals and patients with periodontitis. Using dual LC-MS platforms and deep-learning–assisted data...
MassID™ Confidence-Driven Untargeted Metabolomics
Advancing Untargeted Metabolomics Data Analysis with MassID™ MassID™ is Panome Bio’s identification engine for Next-Generation Metabolomics®, designed to turn complex untargeted metabolomics data into confident metabolite identifications. By evaluating detected...